Imaging Pulmonary NF-κB Activation and Drug Effects
Author Information
Author(s): Dan Ansaldi, Hod Eldad A., Fabio Stellari, Jae-Beom Kim, Ed Lim, Mark Roskey, Kevin P. Francis, Rajendra Singh, Ning Zhang
Primary Institution: Caliper Life Sciences
Hypothesis
Can bioluminescence imaging effectively track NF-κB activation in the lungs and assess the therapeutic effects of specific inhibitors?
Conclusion
The study established a non-invasive imaging approach to monitor NF-κB activation in the lungs, demonstrating that MLN120B and TDZD-8 can effectively suppress this activation.
Supporting Evidence
- Bioluminescence imaging provided adequate sensitivity for tracking NF-κB activation.
- MLN120B and TDZD-8 significantly attenuated NF-κB activation in the lungs.
- Pre-treatment with MLN120B resulted in approximately 70% inhibition of NF-κB activation.
- TDZD-8 completely abolished LPS-induced NF-κB signals in the lungs.
- Significantly decreased levels of pro-inflammatory chemokine MIP-1β were observed with drug treatments.
- Increased levels of anti-inflammatory cytokine IL-10 were detected in treated mice.
Takeaway
Researchers used special mice to see how a part of the immune system called NF-κB works in the lungs and found that two drugs can help calm it down when it gets too active.
Methodology
Mice were transfected with NF-κB reporters and treated with LPS to induce inflammation, followed by imaging to assess NF-κB activation and the effects of drug treatments.
Potential Biases
Potential bias due to the involvement of authors from the pharmaceutical company that developed one of the drugs tested.
Limitations
The study's findings may not fully translate to human conditions due to species differences and the specific model used.
Participant Demographics
Mice used in the study included albino C57BL/6 and BALB/cJ strains.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website